# CURRENT THERAPY IN OBSTETRICS



"鬼龙 明年 明道"八章

CHARLES GLOVER

# **CURRENT THERAPY**

# IN

# **OBSTETRICS**

#### Editor

#### David Charles, M.D.

Formerly, Professor and Chairman Obstetrics and Gynecology Marshall University School of Medicine Huntington, West Virginia

Associate Editor

### Douglas D. Glover, M.D.

Professor of Obstetrics
West Virginia University School of Medicine
Associate Professor of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Publisher

B.C. Decker Inc

3228 South Service Road Burlington, Ontario L7N 3H8

Suite 400

Philadelphia, Pennsylvania 19106

Sales and Distribution

United States and Possessions The C.V. Mosby Company 11830 Westline Industrial Drive Saint Louis, Missouri 63146

Canada

The C.V. Mosby Company, Ltd. 5240 Finch Avenue East, Unit No. 1 Scarborough, Ontario M1S 5P2

and the Middle East

United Kingdom, Europe Blackwell Scientific Publications, Ltd. Osney Mead, Oxford OX2 OEL, England

Australia and New Zealand Harcourt Brace Jovanovich Group (Australia) Pty Limited

30-52 Smidmore Street Marrickville, N.S.W. 2204

Australia

Japan

Igaku-Shoin Ltd.

Tokyo International P.O. Box 5063

1-28-36 Hongo, Bunkyo-ku, Tokyo 113, Japan

Asia

Info-Med Ltd.

B.C. Decker Inc

320 Walnut Street

802-3 Ruttonjee House 11 Duddell Street Central Hong Kong

South Africa

Libriger Book Distributors Warehouse Number 8 "Die Ou Looiery"

Tannery Road

Hamilton, Bloemfontein 9300

South America Inter-Book Marketing Services

Rua das Palmeriras, 32 Apto. 701 222-70 Rio de Janeiro

RJ, Brazil



#### NOTICE

The authors and publisher have made every effort to ensure that the patient care recommended herein, including choice of drugs and drug dosages, are in accord with the accepted standards and practice at the time of publication. However, since research and regulation constantly change clinical standards, the reader is urged to check the product information sheet included in the package of each drug, which includes recommended doses, warnings, and contraindications. This is particularly important with new or infrequently used drugs.

Current Therapy in Obstetrics

ISBN 1-55664-019-6

© 1988 by B.C. Decker Incorporated under the International Copyright Union. All rights reserved. No part of this publication may be reused or republished in any form without written permission of the publisher.

# CURRENT THERAPY IN

# **OBSTETRICS**



### Medical Titles in the Current Therapy Series

Bardin:

Current Therapy in Endocrinology and Metabolism

Bayless:

Current Management of Inflammatory Bowel Disease

Bayless:

Current Therapy in Gastroenterology and Liver Disease

Bayless, Brain, Cherniack:

Current Therapy in Internal Medicine

Brain, Carbone:

Current Therapy in Hematology-Oncology

Callaham:

Current Therapy in Emergency Medicine

Charles:

Current Therapy in Obstetrics

Cherniack:

Current Therapy of Respiratory Disease

Dubovsky, Shore:

Current Therapy in Psychiatry

Eichenwald, Ströder:

Current Therapy in Pediatrics

Foley, Payne:

Current Therapy of Pain

Fortuin:

Current Therapy in Cardiovascular Disease

Garcia, Mastroianni, Amelar, Dubin:

Current Therapy of Infertility

Glassock:

Current Therapy in Nephrology and Hypertension

Jeejeebhoy:

Current Therapy in Nutrition

Johnson:

Current Therapy in Neurologic Disease

Kacmarek, Stoller:

Current Respiratory Care

Kass, Platt:

Current Therapy in Infectious Disease

Lichtenstein, Fauci:

Current Therapy in Allergy, Immunology, and Rheumatology

Nelson:

Current Therapy in Neonatal-Perinatal Medicine

Nelson:

Current Therapy in Pediatric Infectious Disease

Parrillo:

Current Therapy in Critical Care Medicine

Peat.

Current Physical Therapy

Provost, Farmer:

Current Therapy in Dermatology

Rogers:

Current Practice in Anesthesiology

Torg, Welsh, Shephard:

Current Therapy in Sports Medicine

To Jean, whose encouragement, support, and continued confidence make everything possible

#### **CONTRIBUTORS**

#### EROL AMON, M.D.

Assistant Professor of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Washington University School of Medicine; Staff, Barnes Hospital, Saint Louis, Missouri

Tocolytic Agents

#### MARVIN S. AMSTEY, M.D.

Professor, Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry; Chief, Department of Obstetrics and Gynecology, Highland Hospital, Rochester, New York Vaccination in Pregnancy

#### HUGH R. K. BARBER, M.D.

Director, Department of Obstetrics and Gynecology, Lenox Hill Hospital, New York, New York Malignant Disease in Pregnancy

## JAMES A. BARROWMAN, B.Sc., Ph.D., M.B., Ch.B., F.R.C.P.(Lond), F.R.C.P.(C), F.A.C.P.

Professor of Medicine (Gastroenterology), Memorial University of Newfoundland Faculty of Medicine, St. John's, Newfoundland, Canada Gastrointestinal Tract Disorders

#### VANESSA A. BARSS, M.D.

Assistant Professor of Obstetrics and Gynecology, Harvard Medical School; Staff, Brigham and Women's Hospital, Boston, Massachusetts Erythroblastosis Fetalis

#### ALAN S. BERKELEY, M.D.

Associate Professor of Obstetrics and Gynecology, Cornell University Medical College; Associate Attending Obstetrician and Gynecologist, New York Hospital, New York, New York Prophylactic Antibiotics in Obstetrics

#### RICHARD L. BERNSTINE, M.D.

Professor of Obstetrics and Gynecology, Northeastern Ohio Universities College of Medicine; Director of Obstetrics and Gynecology and Education for Obstetrics and Gynecology, St. Elizabeth Hospital Medical Center, Youngstown, Ohio

Missed Abortion

#### MAX BORTEN, M.D., J.D.

Associate Professor of Obstetrics and Gynecology, Harvard Medical School; Director, Division of Medical Gynecology, Beth Israel Hospital and Member, Massachusetts Bar, Boston, Massachusetts Current Medicolegal Issues

#### PETER C. BOYLAN, M.B., M.R.C.O.G.

Lecturer, Department of Obstetrics and Gynaecology, University College Dublin; Consultant Obstetrician Gynaecologist, National Maternity Hospital, Dublin, Ireland

Obstetric Management of the Growth-Retarded Baby

#### ROBERT C. CEFALO, M.D., Ph.D.

Professor, Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina Planned Prenatal Care: Key to the Future

#### WELDON CHAFE, M.D., F.R.C.S.(C), F.A.C.O.G.

Assistant Professor, Division Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida Choriocarcinoma—Gestational Trophoblastic Neoplasia

#### DAVID CHARLES, M.D., F.A.C.O.G., F.R.C.O.G.

Formerly, Professor and Chairman, Department of Obstetrics and Gynecology, Marshall University School of Medicine; Chief of Obstetrics and Gynecology Service, St. Mary's Hospital, Huntington, West Virginia Cervical Incompetence Syphilis in Pregnancy

Syphilis in Pregnancy Yeast Vaginitis Ectopic Pregnancy Spontaneous Abortion Abruptio Placentae

#### NEEOo W. CHIN, M.D.

Clinical Instructor and Senior Fellow, Division of Reproductive Endocrinology, Ohio State University Hospitals, Columbus, Ohio Thyroid Disorders in Pregnancy

#### WAYNE R. COHEN, M.D.

Associate Professor of Obstetrics and Gynecology, Albert Einstein College of Medicine of Yeshiva University; Director of Obstetrics and Gynecology, Bronx Municipal Hospital Center, Bronx, New York Fetal Heart Rate Monitoring

#### SUSAN M. COX, M.D.

Jack A. and Signe Pritchard Fellow in Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas

Urinary Tract Infections

#### ROBERT K. CREASY, M.D.

Emma Sue Hightower Professor of Obstetrics and Gynecology and Chairman, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Texas Medical School; Attending Physician, Chief of Obstetrics and Gynecology, Hermann Hospital, Houston, Texas

Obstetric Management of the Growth-Retarded Baby

#### WARREN M. CROSBY, M.D.

Professor of Obstetrics and Gynecology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

Nutrition in Pregnancy

#### DWIGHT P. CRUIKSHANK, M.D., F.A.C.O.G.

Professor of Obstetrics and Gynecology, University of Utah School of Medicine; Vice Chairman, Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah

Pregnancy-Induced Hypertension

#### F. GARY CUNNINGHAM, M.D.

Professor and Chairman, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas

Urinary Tract Infections

#### LAWRENCE D. DEVOE, M.D.

Associate Professor, Department of Obstetrics and Gynecology and Director, Maternal-Fetal Medicine Section, Medical College of Georgia School of Medicine, Augusta, Georgia

Antepartum Fetal Testing

#### RICHARD C. DICKSON, M.D.

Instructor, Division of Maternal-Fetal Medicine, Medical University of South Carolina College of Medicine, Charleston, South Carolina

Breech Presentation

#### JOAN V. EGGERT, R.D., M.P.H., M.D.

Faculty Lecturer, Perinatal Nutrition; Clinical Instructor, Department of Obstetrics and Gynecology, University of Nebraska Medical Center, Omaha, Nebraska Parenteral and Enteral Nutrition in Pregnancy

#### DAVID A. ESCHENBACH, M.D.

Professor, Department of Obstetrics and Gynecology, University of Washington School of Medicine; Chief, Division of Gynecology, University Hospital and Harborview Medical Center, Seattle, Washington Bacterial Vaginosis in Pregnancy

#### BISHARA J. FREIJ, M.D.

Assistant Professor of Pediatrics, Division of Infectious Diseases, Georgetown University School of Medicine; Attending Physician, Georgetown University Children's Medical Center, Washington, D.C.

Gestational Herpesvirus Infections

#### EMANUEL A. FRIEDMAN, M.D., Sc.D.

Professor, Obstetrics and Gynecology, Harvard Medical School and Health Sciences and Technology, Massachusetts Institute of Technology; Obstetrician-Gynecologist-in-Chief, Beth Israel Hospital, Boston, Massachusetts

Dysfunctional Labor

#### FREDRIC D. FRIGOLETTO Jr., M.D.

William Lambert Richardson Professor of Obstetrics. Harvard Medical School; Chief, Maternal-Fetal Medicine and Director of Obstetrics, Brigham and Women's Hospital, Boston, Massachusetts

Erythroblastosis Fetalis

#### STEVEN G. GABBE, M.D.

Professor and Chairman, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, Ohio

Diabetes in Pregnancy

#### RONALD S. GIBBS, M.D.

Jane and Roland Blumberg Professor, Department of Obstetrics and Gynecology, University of Texas Medical School, San Antonio, Texas Postpartum Infection

#### DOUGLAS D. GLOVER, B.S. Pharm., M.D.

Professor of Obstetrics and Gynecology, West Virginia University School of Medicine and Associate Professor of Clinical Pharmacy, West Virginia University School of Pharmacy; Staff, West Virginia University Hosptial, Morgantown, West Virginia

Ectopic Pregnancy Spontaneous Abortion Abruptio Placentae Lactation Mastitis Drug Excretion in Human Milk

#### HAMID A. HADI, M.D.

Associate Professor of Obstetrics and Gynecology and Director, Division of Maternal-Fetal Medicine, East Carolina University School of Medicine, Greenville, North Carolina

Renal Transplantation in Pregnancy

#### WILLIAM N. P. HERBERT, M.D.

Associate Professor, University of North Carolina School of Medicine; Attending Physician, North Carolina Memorial Hospital, Chapel Hill, North Carolina Amniotic Fluid Tests of Fetal Maturity

#### WILLIAM M. HOLLS III, M.D.

Assistant Professor of Obstetrics and Gynecology, University of Tennessee College of Medicine; Associate Medical Director, Regional Perinatal Center, University of Tennessee Memorial Hospital, Knoxville, Tennessee Intrauterine Fetal Demise

#### EDGAR O. HORGER III, M.D.

Professor of Obstetrics and Gynecology and Radiology and Director of Maternal-Fetal Medicine, Medical University of South Carolina College of Medicine, Charleston, South Carolina

Cesarean Section

#### JAY D. IAMS, M.D.

Associate Professor, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Ohio State University College of Medicine, Columbus, Ohio Premature Rupture of the Membranes

#### LESLIE IFFY, M.D., F.R.C.S.(C)

Professor of Obstetrics and Gynecology, University of Medicine and Dentistry, New Jersey Medical School; Director, Division of Maternal-Fetal Medicine, University Hospital, Newark, New Jersey Placenta Previa

#### DAVID Z. KITAY, M.D.

Staff Physician and Obstetrician Gynecologist, Halifax Hospital Medical Center, Daytona Beach, Florida Anemia in Pregnancy Hemoglobinopathies

#### MOON H. KIM, M.D.

Professor of Reproductive Endocrinology, Ohio State University College of Medicine; Director, Division of Reproductive Endocrinology, The University Hospitals, Columbus, Ohio

Thyroid Disorders in Pregnancy

#### JEFFREY C. KING, M.D.

Assistant Professor, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Georgetown University School of Medicine, Washington, D.C.

Oligohydramnios

#### MARK B. LANDON, M.D.

Assistant Professor of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Ohio State University College of Medicine, Columbus, Ohio

Diabetes in Pregnancy

#### ALVIN LANGER, M.D.

Professor of Obstetrics and Gynecology, Northeastern Ohio Universities College of Medicine, Rootstown; Academic Director of Obstetrics and Gynecology, Aultman Hospital, Canton, Ohio Intrauterine Fetal Demise

#### BRYAN LARSEN, Ph.D.

Associate Professor of Microbiology and Obstetrics and Gynecology, Marshall University School of Medicine, Huntington, West Virginia Syphilis in Pregnancy Yeast Vaginitis

#### J. PATRICK LAVERY, M.D.

Clinical Professor, Department of Obstetrics and Gynecology, Michigan State University College of Human Medicine, East Lansing; Perinatologist, Bronson Methodist Hospital, Kalamazoo, Michigan Premature Labor

## DESMOND J. LEDDIN, M.B., M.R.C.P.(I), F.R.C.P.(C)

Assistant Professor of Medicine (Gastroenterology), Memorial University of Newfoundland Faculty of Medicine, St. John's, Newfoundland, Canada Gastrointestinal Tract Disorders

#### RICK W. MARTIN, M.D.

Assistant Professor, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine, Jackson, Mississippi Liver Disease

#### PHILIP B. MEAD, M.D.

Clinical Professor of Obstetrics and Gynecology, University of Vermont College of Medicine; Hospital Epidemiologist, Medical Center Hospital of Vermont, Burlington, Vermont

Group B Streptococcal Sepsis

#### RICHARD K. MILLER, Ph.D.

Associate Professor of Obstetrics and Gynecology and Pharmacology and Toxicology, University of Rochester School of Medicine and Dentistry, Rochester, New York Infectious Disease Therapy in Pregnancy

#### HOWARD L. MINKOFF, M.D.

Associate Professor of Obstetrics and Gynecology and Director of Maternal-Fetal Medicine, State University of New York College of Medicine, Health Sciences Center, Brooklyn, New York

Acquired Immunodeficiency Syndrome

#### LINDA S. MORGAN, M.D., F.A.C.O.G.

Associate Professor and Director of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida

Choriocarcinoma—Gestational Trophoblastic Neoplasia

#### JOHN C. MORRISON, M.D.

Director, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine, Jackson, Mississippi Liver Disease

#### MAURICE A. MUFSON, M.D., F.A.C.P.

Professor and Chairman, Department of Medicine, Marshall University School of Medicine and Associate Chief of Staff of Research, Veterans Administration Medical Center; Attending Physician, Cabell Huntington Hospital and St. Mary's Hospital, Huntington, West Virginia

Respiratory Diseases

#### NANCY J. MUNN, M.D.

Associate Professor of Medicine, Marshall University School of Medicine and Chief of Pulmonary Section, Veterans Administration Medical Center; Attending Physician, Cabell Huntington Hospital and St. Mary's Hospital, Huntington, West Virginia

Respiratory Diseases

#### JAMES A. O'LEARY, M.D.

Professor of Obstetrics and Gynecology, University of Medicine and Dentistry, New Jersey Medical School, Newark; Chairman, Department of Obstetrics and Gynecology, Jersey City Medical Center, Jersey City, New Jersey

Postpartum Hemorrhage

#### MARY D. PEOPLES-SHEPS, R.N., Dr. P.H.

Assistant Professor of Maternal and Child Health, School of Public Health, University of North Carolina, Chapel Hill, North Carolina

Planned Prenatal Care: Key to the Future

#### ROY H. PETRIE, M.D., Sc.D.

Professor of Obstetrics and Gynecology, Washington University School of Medicine; Director, Division of Maternal-Fetal Medicine, Washington University Medical Center and Obstetrical Service, Barnes Hospital, Saint Louis, Missouri

Tocolytic Agents

#### W. SOYINI POWELL, M.D.

Director, Division of Gynecology, Hahnemann University Hospital, Philadelphia, Pennsylvania Trichomoniasis During Pregnancy

## WILLIAM E. M. PRYSE-PHILLIPS, M.D. F.R.C.P.(C), F.R.C.P.

Professor of Medicine (Neurology), Memorial University of Newfoundland Faculty of Medicine; Chief of Neurology, General Hospital, Health Sciences Centre, St. John's, Newfoundland, Canada Neurologic Disorders

#### JAMES G. PULLANO, M.D., M.B.A.

Instructor and Fellow, Division of Maternal-Fetal Medicine, University of Medicine and Dentistry, New Jersey Medical School, Newark, New Jersey Placenta Previa

#### WILLIAM F. RAYBURN, M.D.

Associate Professor, Department of Obstetrics and Gynecology and Pharmacology, University of Nebraska College of Medicine; Director, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Nebraska Medical Center, Omaha, Nebraska Parenteral and Enteral Nutrition in Pregnancy

#### KENNETH J. REAMY, M.D., M.P.H.

Associate Professor, Department of Obstetrics and Gynecology and Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, Morgantown, West Virginia Sexuality in Pregnancy and the Puerperium

#### ROBERTO ROMERO, M.D.

Associate Professor of Obstetrics and Gynecology and Director, Perinatal Research, Yale University School of Medicine, New Haven, Connecticut Coagulopathies in Obstetrics

#### LUIS SANCHEZ-RAMOS, M.D.

Assistant Professor, Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville; Director, Maternal-Fetal Medicine, University Hospital, Jacksonville, Florida

Prostaglandins

#### JOHN W. SEEDS, M.D.

Associate Professor, Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina Fetal Therapy

#### JOHN L. SEVER, M.D., Ph.D.

Chief, Infectious Diseases Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland Gestational Herpesvirus Infections

#### YOGESH G. SHAH, M.D.

Clinical Associate Professor of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, New York Infectious Disease Therapy in Pregnancy

#### WILLIAM N. SPELLACY, M.D.

Professor and Head, Department of Obstetrics and Gynecology, University of Illinois College of Medicine, Chicago, Illinois Postdate Pregnancy

#### MICHAEL R. SPENCE, M.D., M.P.H

Professor and Chairman, Department of Obstetrics and Gynecology, Hahnemann University School of Medicine, Philadelphia, Pennsylvania Trichomoniasis During Pregnancy

#### RICHARD L. SWEET, M.D.

Professor of Obstetrics, Gynecology, and Reproductive Sciences, University of California School of Medicine; Chief of Obstetrics and Gynecology, San Francisco General Hospital Medical Center, San Francisco, California Chlamydia Trachomatis Infection

#### KENT UELAND, M.D.

Professor and Chairman, Department of Gynecology and Obstetrics, Stanford University School of Medicine; Chief of Obstetrics and Gynecology, Stanford University Medical Center, Stanford, California Heart Disease

#### J. PETER VAN DORSTEN, M.D.

Associate Professor of Obstetrics and Gynecology and Director of Maternal-Fetal Medicine, Virginia Commonwealth University Medical College, Richmond, Virginia Breech Presentation

#### HUNG N. WINN, M.D.

Assistant Professor of Obstetrics and Gynecology, Washington University School of Medicine; Attending Physician, Barnes Hospital, Saint Louis, Missouri Coagulopathies in Obstetrics

#### STEVEN S. WITKIN, Ph.D.

Associate Professor of Immunology and Director, Immunology Division, Department of Obstetrics and Gynecology, Cornell University Medical College, New York, New York Immunology of Pregnancy and Spontaneous Abortion

#### FRANK R. WITTER, M.D.

Assistant Professor, The Johns Hopkins University School of Medicine; Active Staff, The Johns Hopkins Hospital, Baltimore, Maryland Drug Abuse

#### ROBERT A. WOLK, Pharm.D.

Clinical Assistant Professor, University of Michigan College of Pharmacy; Clinical Pharmacist, University of Michigan Medical Center, Ann Arbor, Michigan Parenteral and Enteral Nutrition in Pregnancy

#### FREDERICK P. ZUSPAN, M.D.

Professor, The Richard Meiling Chair, Obstetrics and Gynecology, Ohio State University College of Medicine; Faculty, Ohio State University Hospitals, Columbus, Ohio Chronic Hypertension in Pregnancy Modern medicine is like a tree whose branches, which divide so majestically, require the invisible roots that represent the strength of the sciences from which therapy grows. So important are the basic concepts that I would say with Democritis, "Rather would I explain the cause of a single fact than become King of the Persians."

With the rapid growth of new knowledge fostered by important discoveries, together with the increasing recognition that nature is of one piece, I have the pleasure of being able to explain the cause of many facts that have led to an ever-improving basis for therapy in obstetrics.

During the past several years, there has been an extensive reappraisal of the physiologic changes with pregnancy and its associated disorders, and there has been a concomitant refinement of diagnostic procedures accompanied by a sounder evaluation of therapeutic approaches, which remain of primary concern to the physician.

Clinical management is the central theme of this book, which is destined primarily for those who practice obstetrics, but it will also serve as a useful reference tool for anyone whose practice includes the gravid patient. Chapters have been written expressly for this book by a distinguished cadre, carefully selected for their clinical and investigational interest in the assigned topics, as well as their status as authorities in the field. Their views on current management have been succinctly portrayed, and the presentations are devoid of extraneous material. Thus, the book represents an authoritative distillation of current thought that is well ordered and representative of accepted obstetric practice.

A book of this type would be impossible without the wholehearted support of the contributors. The Editor wishes to thank the staff of B.C. Decker, specifically Mary Mansor for her unstinted assistance and guidance. Finally, as with any such enterprise that has many contributors, one cannot embark along the course of such a volume without a secretary who is not only capable, but has the patience of Job, and I wish therefore to express my sincere and heartfelt appreciation to Nancy Urban.

David Charles, M.D.

## **CONTENTS**

| PRENATAL CARE  |    | Respiratory Diseases  | 88  |
|--|----|---|-----|
| Planned Prenatal Care: Key to the                      | 4  | Nancy J. Munn   |     |
| Future   | 1  | Liver Disease   | 92  |
| Nutrition in Pregnancy                                 | 8  | Neurologic Disorders  | 100 |
| Parenteral and Enteral Nutrition in Pregnancy          | 18 | Thyroid Disorders in Pregnancy  | 109 |
| Robert A. Wolk   |    | Heart Disease   | 115 |
| Amniotic Fluid Tests of Fetal Maturity                 | 27 | Chronic Hypertension in Pregnancy                                       | 123 |
| Obstetric Management of the Growth-Retarded Baby       | 34 | Frederick P. Zuspan  Diabetes in Pregnancy                              | 131 |
| Pregnancy-Induced Hypertension<br>Dwight P. Cruikshank | 40 | Immunology of Pregnancy and Spontaneous Abortion                        | 138 |
| Oligohydramnios  | 46 | Steven S. Witkin  Renal Transplantation in Pregnancy                    | 143 |
| Sexuality in Pregnancy and the                         |    | Hamid A. Hadi   |     |
| Puerperium   | 53 | Infection   |     |
| Antepartum Fetal Testing                               | 60 | Infectious Disease Therapy in Pregnancy                                 | 149 |
| Cervical Incompetence                                  | 67 | Richard K. Miller   | 150 |
| Drug Abuse   | 70 | Gestational Herpesvirus Infections<br>Bishara J. Freij<br>John L. Sever | 156 |
| Medical Disorders                                      |    | Trichomoniasis During Pregnancy W. Soyini Powell Michael R. Spence      | 163 |
| Gastrointestinal Tract Disorders                       | 74 | Vaccination in Pregnancy  | 164 |
| Anemia in Pregnancy                                    | 83 | Prophylactic Antibiotics in Obstetrics<br>Alan S. Berkeley              | 170 |
| David Z. Kitay  Hemoglobinopathies                     | 85 | Acquired Immunodeficiency Syndrome  Howard L. Minkoff                   | 176 |

| Chlamydia Trachomatis Infection Richard L. Sweet     | 180 | Tocolytic Agents                                    | 267 |
|--|-----|---|-----|
| Postpartum Infection                                 | 184 | Roy H. Petrie  Premature Labor                      | 271 |
| Group B Streptococcal Sepsis                         | 189 | J. Patrick Lavery  Postdate Pregnancy               | 278 |
| Bacterial Vaginosis in Pregnancy David A. Eschenbach | 195 | William N. Spellacy  Dysfunctional Labor            | 283 |
| Syphilis in Pregnancy                                | 201 | Emanuel A. Friedman  Prostaglandins                 | 286 |
| Yeast Vaginitis                                      | 206 | Intrauterine Fetal Demise                           | 290 |
| Urinary Tract Infections                             | 209 | Breech Presentation                                 | 295 |
| OBSTETRIC HEMORRHAGES                                |     | THE FETUS   |     |
| Postpartum Hemorrhage                                | 216 | Erythroblastosis Fetalis                            | 302 |
| Coagulopathies in Obstetrics                         | 222 | Vanessa A. Barss  Fetal Heart Rate Monitoring       | 305 |
| Ectopic Pregnancy                                    | 237 | Fetal Therapy                                       | 311 |
| Missed Abortion                                      | 241 | THE BREAST  |     |
| Spontaneous Abortion                                 | 245 | Lactation   | 324 |
| Douglas D. Glover Placenta Previa                    | 248 | Mastitis  | 331 |
| James G. Pullano<br>Leslie Iffy                      |     | Drug Excretion in Human Milk Douglas D. Glover      | 334 |
| Abruptio Placentae                                   | 253 | Malignant Disease                                   |     |
| LABOR AND DELIVERY                                   |     | Malignant Disease in Pregnancy                      | 340 |
| Premature Rupture of the Membranes                   | 258 | Choriocarcinoma—Gestational Trophoblastic Neoplasia | 351 |
| Cesarean Section                                     | 262 | Current Medicolegal Issues                          | 360 |

## PRENATAL CARE

# PLANNED PRENATAL CARE: KEY TO THE FUTURE

MARY D. PEOPLES-SHEPS, R.N., Dr.P.H. ROBERT C. CEFALO, M.D., Ph.D.

Prenatal care addresses many of the medical and obstetric problems that occur during the prenatal period and that are discussed in other chapters of this book. It is the medium through which the screening, diagnosis, and therapies discussed in these chapters usually take place. In addition, prenatal care, from its earliest inception, was intended to prevent the onset of morbidity during pregnancy by identifying those at risk and reducing their risks and by promoting healthy behaviors among all pregnant women.

Specifically, prenatal care consists of a series of activities that are designed to:

- 1. Detect physical and psychosocial risk factors and early signs of asymptomatic diseases that may adversely affect mother and fetus.
- 2. Diagnose and treat maternal and fetal abnormalities as soon as they appear.
- Provide guidance and education regarding behaviors and signs that may influence maternal and fetal wellbeing as well as for delivery arrangements and postpartum, family planning, and infant care arrangements.

Over time, as screening and diagnostic tests and problem-specific therapies developed, certain aspects of prenatal care, such as history-taking, selected laboratory tests, and specific schedules of visits, became "routine." In theory, routinization of these components of prenatal care allowed all women to benefit from important advances in the field relatively quickly. In practice, it also promoted a system of care in which higher priority could be assigned to objective standards of care rather than to individual patient needs.

Although adherence to standards of prenatal care has never been monitored regularly, there is evidence that some providers have deviated from what might be considered routine for many years. These deviations are due, at least in part, to variations in accepted standards across obstetric textbooks and professional societies and to the responsiveness of providers to individual patient needs.

In the latter half of the 1980s, there is a general recognition that routine prenatal care no longer exists. Still remaining are standards for certain activities, some of which are controversial. Other routines, such as the number and frequency of prenatal visits and the content of those visits, are in flux. Prenatal care is becoming a process that is planned with each individual woman based on her specific needs as derived from her history, laboratory findings, physical examination, and the progress of the current pregnancy. Prenatal care, of necessity, is mercurial and dynamic.

#### **CONTROVERSIAL ISSUES**

#### History—The Cornerstone of Prenatal Care

**Background.** A careful, systematic history is critical to identify whether there were problems in previous pregnancies that might repeat themselves in the present pregnancy and to detect known medical problems or conditions and behavioral or social circumstances that might compromise the current pregnancy. It constitutes part of the baseline information that should be available for every prenatal patient. The history, therefore, should be targeted, but at the same time it should be broad enough to detect a range of clues to potential problems. A prenatal history should include the following:

- 1. Medical history: diseases, conditions, and surgeries throughout the life of the individual.
- 2. Obstetric history: details on the course and outcome of each previous pregnancy.
- 3. Gynecologic history: experience with and treatment of gynecologic problems, including sexually transmitted diseases and contraceptive utilization.
- 4. Immunization status for communicable diseases.
- 5. Family medical and genetic history.
- 6. Nutritional problems and treatments.
- 7. Selected behaviors, including ingestion of cigarettes, alcohol, and drugs, and work outside the home.
- Social history: marital status, family problems, financial status.

To complete a history, all prior medical records should be obtained and reviewed. The history should be taken as early in pregnancy as possible, preferably at the first prenatal visit, before 12-weeks gestation.

Each positive finding in a history suggests one or more activities that should be undertaken. The management of many specific medical and obstetric problems is given in other chapters of this volume. In addition to those, appropriate courses of action for behavioral, social, and nutritional problems also require attention. They are addressed below in the section on referral networks.

Controversy. What is controversial about history-taking is not whether it should be done but how it should be recorded so that the information can be put to greatest use. In the past 15 years, a number of forms for recording historical data as well as other information about the pregnancy have been developed. Some of the forms require calculation of weighted scores that determine the risk classification of the pregnancy (e.g., high, medium, low). Others do not yield scores, but relevant problems can be recorded and reviewed in a simple but systematic fashion.

The extent to which either type of instrument is used by providers of prenatal care is unknown. Moreover, the relative value of one type of form over another in improving the management of selected pregnancies has not been examined. The greatest amount of controversy is with regard to the instruments that yield weighted scores. There are several reasons for this:

- The instruments have not been validated or modified for differences in age, race, social class, or geographic area.
- 2. Cut-points for high risk differ not only by population group but also by outcome.
- The instruments are susceptible to mechanistic application, to becoming ends in themselves rather than tools for intervention, and to producing anxiety in the women labeled high-risk (whether the label is correct or not).

In addition to controversies surrounding the type of form that is most appropriate for recording a history, there is some debate about what items should be included in a history-taking instrument. Most of the forms available today request very little information on nonclinical factors, such as social, behavioral, and environmental risks. Yet, some of these factors (e.g., smoking) constitute major preventable causes of perinatal morbidity.

Recommendations. Although controversies exist, it is reasonable to conclude that: (1) a careful, systematic history should be taken on each pregnant woman, and the information should be recorded in a systematic manner. (2) A check-off history can be a helpful tool if it is used as a reminder to increase communication between humans, not as a short cut to abbreviated care. (3) One specific tool for recording historical and other relevant information during pregnancy cannot be recommended over another. All have positive and negative attributes. (4) Careful attention should be given to the nonclinical

characteristics that may not be well represented in available instruments but are important determinants of pregnancy outcome, some of which (e.g., work place environment, consumption of alcohol and drugs) may require sensitive probing during the process of history-taking.

#### **Screening Tests**

Prenatal care includes a set of laboratory tests that are used to screen for selected conditions that can compromise the mother or infant or both. Recommendations for these tests have evolved over time as the capabilities to identify disorders and the technology to do screening tests have developed. For the most part, tests were absorbed into routine prenatal care before the clinical trials required to establish efficacy were conducted. As a result, there is some remaining controversy associated with several of them.

#### Hemoglobin/Hematocrit

**Background.** A blood test for hemoglobin or hematocrit levels is done at the first prenatal visit, early in the third trimester, and at other times, as needed. It is considered important to assess hemoglobin levels at the first visit in order to detect anemia early in pregnancy so that the cause may be ascertained and the condition treated. Monitoring hemoglobin levels over time allows an assessment of the amount of change in levels and provides for additional treatment, if necessary, before the blood loss associated with delivery and the postpartum period occurs.

Controversy. Since pregnancy is characterized by a dilutional anemia that is most evident at 28 to 32 weeks and is apparently normal, there is controversy about the "ideal" prenatal hemoglobin and hematocrit values. Nevertheless, values that are likely to be abnormal (e.g., <11 g per deciliter in the second and third trimesters) can be identified so that further investigation can be initiated.

Recommendations. (1) A blood sample for hemoglobin and hematocrit readings should be drawn at the first prenatal visit. The need for additional laboratory evaluation should be determined by historical factors or unusual clinical findings. Ethnic or social circumstances may dictate the need for special testing, such as sicklecell test or hemoglobin electrophoresis or both. (2) A hemoglobin of less than 10 g per deciliter in the early part of pregnancy deserves further evaluation. (3) Early in the third trimester, repeat hemoglobin and hematocrit evaluations should be done as dilutional anemia is anticipated. If the hematocrit increases, one may become suspicious of contracted blood volume and look for evidence of intrauterine growth retardation or preeclampsia.

#### Cervical Cytology

Background. A cervical smear to detect invasive cancer of the cervix as well as the premalignant forms—cancer in situ and cervical dysplasia—is recommended once during pregnancy, at the first prenatal visit. The smear is recommended during pregnancy because (1) this period is the only time many women are in contact with a health care provider, (2) it can be done easily during a vaginal examination, and (3) it promotes coverage of a particularly high-risk group of women, multiparas of low socioeconomic status.

Controversy. Since all women are screened, the screening process covers a number of women who are at low risk. Studies in Great Britain have shown that the probability of developing cervical cancer—in the short term (10 years)—among women less than 25 years old is very low. In addition, women who are tested during pregnancy are more likely to have a higher rate (about six times as great) of false-positive tests than those in the general population. Such a high false-positive rate for young women during pregnancy limits the acceptability of universal screening because of the stress likely to be engendered by a false-positive finding. Also, although a few young women die each year as a result of cervical cancer, the death rate is very low when compared with that of older women. An alternative approach to screening for cervical cancer would involve using age as the primary screening test, that is, routine smears would only be done on women age 25 and older. This approach has not received widespread support, however, because the Papanicolaou smear can also yield evidence of sexually transmitted diseases, such as condylomata or herpes.

**Recommendation.** Because the Papanicolaou smear can detect conditions other than cancer and its premalignant manifestations, it is recommended for all women at least once during pregnancy.

#### Dipstick Urinalysis

**Background.** A simple and safe method for testing the urine for selected components is the dipstick urinalysis at each visit. The test is usually done for two reasons: (1) to detect proteinuria, which is a sign of preeclampsia and may indicate acute or chronic renal disease, and (2) to detect glycosuria, which may be a sign of gestational diabetes. Random urine testing for proteinuria is considered cost-effective, but the value of testing for glycosuria is controversial.

**Controversy.** Reliable estimates of the sensitivity and specificity of this test for predicting gestational diabetes have not been determined, although the random timing of the test would suggest that it would not be highly predictive. Moreover, glycosuria during pregnancy is common and frequently physiologic.

On the other hand, persistent glycosuria is associated with maternal diabetes and should signal the need for further investigation.

**Recommendations.** (1) A dipstick test of the urine to detect proteinuria is recommended at each prenatal visit. (2) To detect persistent glycosuria, which should signal the need for further investigation of maternal diabetes, a dipstick reading at each visit is also recommended.

#### **Blood Tests for Glucose**

Background. Currently, carbohydrate intolerance screening is not part of prenatal care unless risk factors for diabetes mellitus are present. However, detection of gestational diabetes is essential because the condition has been associated with maternal and fetal complications. When risk factors, such as family history of diabetes, previous macrosomic infant, poor obstetric history, or persistent glycosuria, are used as indicators for further screening for gestational diabetes, 30 to 40 percent of affected patients are not detected. A more sensitive screening procedure involves administration of 50 g of glucose orally, followed in 1 hour by a plasma glucose test. A definitive diagnosis of gestational diabetes should be based on a 100-g, 3-hour oral glucose tolerance procedure.

Controversy. At present, there is no clear evidence of the cost-effectiveness of universal 1-hour screening of plasma for glucose tolerance. As a result, recommendations vary. The American Diabetes Association and the Centers for Disease Control have endorsed universal screening of all pregnant women. The American College of Obstetricians and Gynecologists recommends screening of women who are 30 years of age or older. The recommendation further states that if any risk factors are present, screening should be performed regardless of age.

**Recommendations.** (1) All pregnant women should be screened for glucose intolerance between 24 to 28 weeks using a 50-g oral glucose load, followed by a 1-hour plasma glucose test. (2) If risk factors are present, a glucose screen should be performed early in pregnancy. If that screening test is negative, it should be repeated at 24 or 28 weeks.

#### Urine Culture

Background. Routine screening for asymptomatic bacteriuria is not recommended at present in the United States, although interest is growing. Women with bacteriuria of pregnancy are significantly more likely to develop pyelonephritis, which in turn is closely associated with perinatal mortality and low infant birth weight. The relationships among these factors are not clearly understood, but treatment of bacteriuria significantly lowers the risk of pyelonephritis from 28 to 3 percent and, through that route, may affect the incidence of low birth weight in a positive direction.

Controversy. The incidence of asymptomatic bac-